Cosmos Health's Antiseptic Brands Exceed $1.5M Annual Sales, Target $7.4M Revenue by 2028
COSM is trading near its 52-week low of $0.195 (11% above the low).
Summary
Cosmos Health reported over $1.5 million in annualized sales for its C-Scrub and C-Sept antiseptic brands in the UK and Greece, achieving gross margins above 70%. The company plans EU expansion, targeting $7.4 million in revenue and $5.3 million in gross profit from these brands by 2028. This positive operational update provides specific product growth details amidst recent SEC filings that included "going concern" warnings, increased losses, and significant share dilution. For a company with a low market capitalization, these current sales and future projections represent a material growth driver with high margins, which could help offset some of the reported financial risks.
At the time of this announcement, COSM was trading at $0.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.5M. The 52-week trading range was $0.20 to $1.32. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.